The leading assignee in this dataset holds 87 of the 1,928 records in scope, with the fifth-ranked filer at 60 and the tenth at 39. The top five combined account for 17.5% of all records, which is real concentration but still leaves the majority of filings spread across a long tail of academic centres, national research agencies and smaller biotech entrants. No single commercial company dominates the way you’d see in some other life-science patent fields.

Filing peaked in 2019 at 181 records and has since pulled back; the clearest complete-year comparison shows a -32% change from 127 records in 2021 to 86 in 2024. Because publication lags filing by roughly 18 months, the 2025-2026 counts in any dataset will look artificially low and should not be read as continued decline. Based on the last fully-settled years, though, the field has genuinely cooled from its 2019 high.

US20250075187A1, filed by ORGANOIDSCIENCES LTD. and published in March 2025, claims a specific medium composition for preparing intestinal organoids, the method of culturing with that medium, and the intestinal organoid produced by that method. That three-layer structure — composition, method, product — means a competitor’s medium would need to differ materially in formulation to avoid the claims, and simply changing the downstream use case doesn’t clear the product claim if the underlying medium is substantially the same. It is representative of a broader pattern in this dataset where medium-composition patents extend their reach through paired method and product claims.